Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas.

HPV NFIX anal cancer integration prognostic factor

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 Nov 2019
Historique:
received: 21 10 2019
revised: 15 11 2019
accepted: 19 11 2019
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 27 11 2019
Statut: epublish

Résumé

The role of human papillomavirus (HPV) in anal squamous cell carcinoma (ASCC) carcinogenesis has been clearly established, involving the expression of viral oncoproteins and optional viral DNA integration into the host genome. In this article, we describe the various mechanisms and sites of HPV DNA insertion and assess their prognostic and predictive value in a large series of patients with HPV-positive ASCC with long-term follow-up. We retrospectively analyzed 96 tumor samples from 93 HPV-positive ASCC patients using the Capture-HPV method followed by Next-Generation Sequencing, allowing determination of HPV genotype and identification of the mechanisms and sites of viral genome integration. We identified five different mechanistic signatures of HPV insertions. The distribution of HPV signatures differed from that previously described in HPV-positive cervical carcinoma (

Identifiants

pubmed: 31766658
pii: cancers11121846
doi: 10.3390/cancers11121846
pmc: PMC6966520
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:3-12
pubmed: 28528688
Dig Liver Dis. 2012 Oct;44(10):803-11
pubmed: 22658644
Ann Oncol. 2014 Sep;25 Suppl 3:iii10-20
pubmed: 25001200
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 1998 Aug;16(8):2613-9
pubmed: 9704710
FASEB J. 2001 Jun;15(8):1445-7
pubmed: 11387252
Hum Pathol. 2013 Jun;44(6):992-1002
pubmed: 23266444
Cancer Lett. 2017 Dec 1;410:124-138
pubmed: 28962832
Curr Mol Med. 2016;16(1):70-82
pubmed: 26695693
Radiother Oncol. 2014 Dec;113(3):331-6
pubmed: 25465729
NPJ Genom Med. 2016 Mar 16;1:16004
pubmed: 29263809
J Clin Oncol. 2009 Oct 20;27(30):5088-93
pubmed: 19770372
J Clin Oncol. 2014 Jun 10;32(17):1812-7
pubmed: 24821878
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
J Gynecol Oncol. 2015 Apr;26(2):111-7
pubmed: 25872892
Int J Cancer. 2015 Jan 1;136(1):98-107
pubmed: 24817381
Cell Rep. 2014 Jun 26;7(6):1833-41
pubmed: 24910434
Genes Chromosomes Cancer. 2018 Dec;57(12):638-644
pubmed: 30264502
Chin J Cancer Res. 2019 Apr;31(2):389-399
pubmed: 31156309
Br J Cancer. 2016 Jun 14;114(12):1387-94
pubmed: 27219019
Cancer Biomark. 2017 Sep 7;20(3):325-331
pubmed: 28800311
J Clin Oncol. 2013 Apr 20;31(12):1569-75
pubmed: 23509304
Head Neck. 2014 May;36(5):750-9
pubmed: 23606404
Clin Cancer Res. 2016 Sep 15;22(18):4735-45
pubmed: 27091409
Cancer Res. 1989 Sep 1;49(17):4677-81
pubmed: 2547512
Br J Cancer. 2015 Apr 14;112(8):1358-66
pubmed: 25871546
Oncogene. 2003 Jun 19;22(25):3977-84
pubmed: 12813471
Front Pharmacol. 2017 Aug 21;8:540
pubmed: 28871224
Nat Commun. 2016 Jul 13;7:12222
pubmed: 27406316
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544-9
pubmed: 25313082
PLoS One. 2014 Feb 24;9(2):e88718
pubmed: 24586376
Cancer Epidemiol. 2013 Dec;37(6):807-12
pubmed: 24139594

Auteurs

Adeline Morel (A)

Institut Curie, Pharmacogenomic Unit, 26 rue d'Ulm, 75248 Paris, France.

Cindy Neuzillet (C)

Institut Curie, Medical Oncology Department, Versailles Saint-Quentin University, 35 rue Dailly, 92210 Saint-Cloud, France.

Maxime Wack (M)

Département d'Informatique Médicale, Biostatistiques et Santé Publique, Hôpital Européen Georges Pompidou, and Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.
Centre de Recherche des Cordeliers, INSERM UMRS1138, Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.

Sonia Lameiras (S)

Institut Curie, Genomics of Excellence (ICGex) Platform, PSL Research University, 26 rue d'Ulm, 75248 Paris CEDEX 05, France.

Sophie Vacher (S)

Institut Curie, Pharmacogenomic Unit, 26 rue d'Ulm, 75248 Paris, France.

Marc Deloger (M)

Institut Curie, Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, 75248 Paris, France.

Nicolas Servant (N)

Institut Curie, Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, 75248 Paris, France.

David Veyer (D)

Laboratoire de virologie, Hôpital Européen Georges Pompidou, and Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.

Hélène Péré (H)

Laboratoire de virologie, Hôpital Européen Georges Pompidou, and Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.

Odette Mariani (O)

Institut Curie, Centre de Ressources Biologiques, 26 rue d'Ulm, 75248 Paris, France.

Sylvain Baulande (S)

Institut Curie, Genomics of Excellence (ICGex) Platform, PSL Research University, 26 rue d'Ulm, 75248 Paris CEDEX 05, France.

Roman Rouzier (R)

Institut Curie, Medical Oncology Department, Versailles Saint-Quentin University, 35 rue Dailly, 92210 Saint-Cloud, France.

Maud Kamal (M)

Institut Curie, Department of Drug Development and Innovation (D3i), Institut Curie Paris & Saint Cloud, 75248 Paris, France.

Elsy El Alam (E)

Institut Curie, Pathology Department, 35 rue Dailly, 92210 Saint-Cloud, France.

Emmanuelle Jeannot (E)

Institut Curie, Pathology Department, 26 rue d'Ulm, 75248 Paris, France.

Alain Nicolas (A)

Institut Curie, PSL Research University, CNRS UMR3244, 75248 Paris, France.

Ivan Bièche (I)

Institut Curie, Pharmacogenomic Unit, 26 rue d'Ulm, 75248 Paris, France.
INSERM U1016, Université Paris Descartes University, 75006 Paris, France.

Wulfran Cacheux (W)

Institut Curie, Medical Oncology Department, Versailles Saint-Quentin University, 35 rue Dailly, 92210 Saint-Cloud, France.
Hôpital Privé Pays de Savoie, Service d'oncologie Médicale, 19 Avenue Pierre Mendès France, 74100 Annemasse, France.

Classifications MeSH